KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey March 19, 2024
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update March 12, 2024
KalVista pill reduces swelling symptoms caused by genetic disease, achieving goal of late-stage study February 23, 2024
KalVista Pharmaceuticals Reports Phase 3 Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema February 23, 2024
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 6, 2023
